MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
CRISPR Therapeutics AG Market Cap 2011-2025 | CRSP
As of December 13, 2025 CRISPR Therapeutics AG has a market cap of $ 4.8 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap CRISPR Therapeutics AG
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.34 B | 6.5 B | 3.64 B | 5.76 B | 10.1 B | 2.85 B | 1.55 B | 1.67 B | 217 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.1 B | 217 M | 3.96 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M |  USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.31 B | $ 25.27 | -2.43 % | $ 1.22 B | USA |
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
445 M | $ 4.75 | 1.61 % | $ 788 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
152 M | $ 3.26 | -3.12 % | $ 252 M | USA |
 |
AlloVir
ALVR
|
49 M | - | 4.14 % | $ 49.1 M | USA |
 |
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
2.05 B | - | -15.15 % | $ 60.3 M |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
Kamada Ltd.
KMDA
|
271 M | $ 7.03 | 0.14 % | $ 260 M |  Israel |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
7.37 B | $ 220.27 | 4.81 % | $ 5 B |  Danmark |
 |
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | Israel |
 |
Enlivex Therapeutics Ltd.
ENLV
|
18.3 M | $ 0.91 | -5.01 % | $ 18.7 M | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.16 B | $ 0.28 | -2.28 % | $ 609 M | Israel |
 |
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.3 | -3.51 % | $ 7.94 B |  Australia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
AstraZeneca PLC
AZN
|
81.2 B | $ 89.78 | -0.57 % | $ 96.9 B | Britain |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Anika Therapeutics
ANIK
|
373 M | $ 9.57 | 0.84 % | $ 140 M | USA |
 |
Brickell Biotech
BBI
|
11.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
8.32 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
117 M | - | -7.31 % | $ 87 M | USA |
 |
Benitec Biopharma
BNTC
|
556 M | $ 12.05 | -7.06 % | $ 496 M | USA |
 |
Aytu BioScience
AYTU
|
15.8 M | $ 2.34 | 2.59 % | $ 14.7 M | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
143 M | - | -19.68 % | $ 18.4 M | Canada |
 |
Arena Pharmaceuticals
ARNA
|
5.65 B | - | -6.81 % | $ 3.04 B | USA |
 |
Aptorum Group Limited
APM
|
4.09 M | $ 1.29 | -3.01 % | $ 7.03 M |  China |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M |  France |
 |
Baudax Bio
BXRX
|
779 K | - | 0.59 % | $ 63 K | USA |
 |
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Catalyst Biosciences
CBIO
|
33.6 M | $ 14.01 | -8.49 % | $ 922 M | USA |
 |
ChromaDex Corporation
CDXC
|
431 M | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
39.8 B | $ 566.18 | -2.56 % | $ 42.9 B | USA |
 |
Cerus Corporation
CERS
|
301 M | $ 2.16 | 0.47 % | $ 399 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
160 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
3.58 M | - | -16.75 % | $ 25.8 M | USA |
 |
Clovis Oncology
CLVS
|
231 M | - | -7.23 % | $ 13 M | USA |
 |
Biogen
BIIB
|
19.3 B | $ 174.42 | 1.11 % | $ 25.4 B | USA |
 |
BioVie
BIVI
|
2.44 M | $ 1.42 | -5.96 % | $ 2.1 M | USA |
 |
Celldex Therapeutics
CLDX
|
1.31 M | $ 27.36 | -2.09 % | $ 1.76 M | USA |
 |
Cortexyme
CRTX
|
70 M | - | -1.05 % | $ 67.1 M | USA |
 |
Cellectar Biosciences
CLRB
|
44.5 M | $ 3.63 | -3.97 % | $ 44.4 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
1.2 B | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
8.59 B | $ 11.54 | 0.87 % | $ 746 M | USA |